ACADIA Pharmaceuticals Inc
Company Profile
Business description
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Contact
12830 El Camino Real
Suite 400
San DiegoCA92130
USAT: +1 858 558-2871
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
654
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
stocks
10 of the cheapest global companies with wide moats
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,089.90 | 7.80 | 0.10% |
| CAC 40 | 8,114.57 | 40.59 | 0.50% |
| DAX 40 | 23,393.23 | 238.66 | 1.03% |
| Dow JONES (US) | 41,472.25 | 369.38 | -0.88% |
| FTSE 100 | 8,705.23 | 24.94 | 0.29% |
| HKSE | 24,740.57 | 595.00 | 2.46% |
| NASDAQ | 17,498.52 | 310.15 | -1.74% |
| Nikkei 225 | 37,845.42 | 448.90 | 1.20% |
| NZX 50 Index | 12,076.85 | 89.29 | -0.73% |
| S&P 500 | 5,607.63 | 67.49 | -1.19% |
| S&P/ASX 200 | 7,860.40 | 6.30 | 0.08% |
| SSE Composite Index | 3,429.76 | 3.63 | 0.11% |